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Introduction: The prevalence of invasive fungal diseases shows an increasing trend. Due to the frequent but
unprofessional usage of antifungal medications, the fungi show decreasing susceptibility towards these agents and
this trend may lead to the emergence of resistant pathogens. There is a great need to develop antifungal medications
with new mechanisms. One of these options is to apply proteins with natural antifungal effects. The objective was
to measure the antifungal efﬁcacy of Xenorhabdus budapestensis in vitro on clinical Candida species (Candida
albicans, Candida lusitaniae, Candida krusei, Candida kefyr, Candida tropicalis, and Candida glabrata).
Materials and methods: We deﬁned the sensitivity of the Candida species towards antibiotics. We conducted
agar diffusion tests with the cleaned biopreparation of X. budapestensis (100%) and its dilutions (80%, 60%, 40%,
and 20%). Zones of inhibition were measured after 24, 48, and 96 hr. Results: Most of the tested Candida species
have shown sensitivity to the biopreparation and its 40% dilution. The area of the zones of inhibition did not
decrease after several days. The most sensitive species was C. lusitaniae and the least sensitive was C. krusei.
Conclusion: We assume that the proteins produced by X. budapestensis have antifungal effect, as the area of the
zones of inhibition did not change.
Keywords: Candida species, antifungal effect, Xenorhabdus budapestensis, resistance
INTRODUCTION
The number of diseases caused by fungi is gradually
increasing. The most common species is Candida albicans,
the other group consists of non-albicans Candida species as
per its frequency [1].
C. albicans is part of the normal human microﬂora, but
under certain circumstances, it may cause superﬁcial or
invasive fungal diseases. It may produce a bioﬁlm on a
biotic or abiotic surface and its adhesion is supported by
adhesins [2]. Its hyphae may produce certain hydrolases,
which promote their entry to the host cell. They are also
capable of easily adapting to various pH levels and other
stress factors within the human body [3].
Candida glabrata is the second most common species, it
has been isolated from human faeces in 1917 [4]. Its growth
temperature optimum is 37 °C, which is the core tempera-
ture of the healthy human body. Its tolerance towards
different stress factors is very high and tolerates the absence
of nutrients well. It is also resistant against the attacks of the
immune system. It has shown high resistance against azole-
type antifungal medications. A protein called adhesin
ensures its adhesion to the cell membrane. It easily produces
bioﬁlm on medical devices, such as catheters [5].
Candida lusitaniae occurs more rarely than the rest of the
Candida species. The ﬁrst reports of this species were pre-
sented in 1979. Its teleomorph form is called Clavispora
lusitaniae. It is resistant to Amphotericin B and produces
haemolysin [6]. The sensitivity towards Amphotericin B can
be increased if combined with ﬂuconazole and 5-ﬂuorocytosine
[7]. One of the reasons behind the resistance is the change in
the biosynthesis of ergosterol. Due to that, the ergosterol
content of the cell membrane decreases [8].
Candida kefyr has been isolated from keﬁr in 1909, its
former name is Candida pseudotropicalis. Its teleomorph
form is the yeast of keﬁr, the Kluyveromyces marxianus [9].
Rarely, it may cause invasive infections, especially simul-
taneously with malignant diseases of the haematopoietic
system [10]. It produces protease, haemolysin, and
phospholipase [6].
The prevalence of Candida krusei is increasing similar to
C. glabrata. It is ﬂuconazole resistant due to the altered
* Corresponding author: Erzsébet Burgettiné Böszörményi;
Faculty of Health Sciences, Department of Epidemiology, Institute
for Health Promotion and Clinical Methodology, Semmelweis
University, Vas utca 17, Budapest H-1088, Hungary; E-mail:
boszormenyie@se‑etk.hu
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License,
which permits unrestricted use, distribution, and reproduction in any medium for non-commercial purposes, provided the original author and
source are credited, a link to the CC License is provided, and changes – if any – are indicated.
ISSN 2630-936X © 2018 The Author(s)
ORIGINAL ARTICLE Developments in Health Sciences 1(3), pp. 57–62 (2018)
DOI: 10.1556/2066.2.2018.17
First published online November 13, 2018
functioning of the P450 isoenzyme [11]. It also
shows decreased resistance to Amphotericin B and
ﬂucytosine. It is likely to produce bioﬁlm [12] and to
produce phospholipase [6].
Candida tropicalis was ﬁrst reported as Oidium tropicale
in 1910. It is a frequently isolated Candida species especially
in cancer patients. It has a strong adhesive feature and easily
produces bioﬁlm [6]. Its prevalence is greatly increased due
to the use of broad-spectrum antibiotics or long-lasting
catheters. The matrix of the bioﬁlm differs from the ones
produced by other species due to its hexosamine content. It is
resistant to Amphotericin B and ﬂuconazole. Its hypha-
producing ability and enzyme production (phospholipase,
protease, and haemolysin) only increase its virulence [6].
The number of C. krusei, C. glabrata, and C. tropicalis
infections also increases gradually.
OBJECTIVES AND METHODOLOGY
The objective of our work is to test the antimicrobial effects
of the protein produced by the Gram-negative insect patho-
gen bacteria Xenorhabdus budapestensis on six Candida
species (C. albicans, C. krusei, C. tropicalis, C. lusitaniae,
C. kefyr, and C. glabrata). The isolated specimens are from
clinical samples.
Our experiment has been motivated by two factors. One
of them is the results originating from the previous testing of
the cell-free culture media (CFCM) and its cleared biopre-
paration [puriﬁed fraction (PF)] of X. budapestensis on
Gram-negative and Gram-positive bacteria originating from
veterinary and human infections [13–16].
The other factor is the experiments conducted with
Xenorhabdus cabanillasii bacteria. This bacterium was able
to inhibit the growth of various ﬁlamentous fungus species,
including Fusarium oxysporum and Candida as well [17]. It
has to be noted that our team has also conducted experiments
with ﬁlamentous fungi (Aspergillus fumigatus, Aspergullus
ﬂavus, and Fuzarium spp.). However, with the clinical
samples, we have not been able to achieve any antifungal
effects that could be considered as lasting. These experiments
prove that there are major differences between the antimi-
crobial proteins of the various Xenorhabdus species.
The antimicrobial agent of X. budapestensis is a
hexapeptide protein, which was named as bicornutin-A back
in 2009 [18]. Researchers in Frankfurt also noted the
antimicrobial effects of X. budapestensis. MALDI spec-
trometry has proven that this hybrid molecule protein is
rich in arginine and contains putrescine and phenylethyla-
min, and was named as fabclavin. Moreover, a 6,848-bp
section of the bicA gene has been discovered, which is
responsible for the production of bicornutin-A. The gene
cluster has been recognised in E.coli DH10B bacteria with
the heterologous expression of the bicA gene [19].
Our work was carried out in the microbiology laboratory
of the Faculty of Health Sciences of Semmelweis University
cooperating with the Research Institute of Bioengineering,
Membrane Technology and Energetics of the University of
Pannonia. We have received the tested Candida species
from the clinical microbiology laboratory of Semmelweis
University.
The process of producing CFCM
The CFCM and the cleaned biopreparation were made from
the Xenorhabdus antimicrobial peptide (XAMP)-producing
primer variant of the DSM-16342T entomopathogenic bac-
teria strain of X. budapestensis, which was able to produce
the substance with the highest antimicrobial effect in previ-
ous studies [20].
The bacterium, which produces the antimicrobial sub-
stance, was grown in lysogeny broth at 25 °C temperature,
shaken at 200 rpm and at increasing levels in three steps.
After reaching the stationary phase, we have centrifuged the
cell culture (15,000 × g, 20 °C, 20 min) and ﬁltered it with a
0.22-μm pore-diameter (Merck Millipore, Merck Kft., An
afﬂiate of Merck KGaA, Darmstadt, Germany) ﬁlter. The
CFCMwas produced from this. A further 3 L of conditioned
CFCMwere cleaned, from which the fraction rich in cleaned
peptides (PF) was prepared.
The prepared solutions were shaken for 48 hr on 150 rpm
with 20 g/L Amberlite® XAD 1180R cation ion-exchange
resin – previously activated in distilled water (121 °C,
30 min) with an autoclave – in order to better adsorb the
bioactive substances. Then, the washing of the resin and
extraction was carried out in multiple steps with applying
methanol solutions of different concentrations in the fol-
lowing order: 1 L sterile distilled water, 500 ml of 25%
MeOH, 3 × 300 ml of 50% MeOH, 3 × 300 ml of 80%
MeOH, and ﬁnally 300 ml cc MeOH, which has been
acidised with 3 ml 2 N HCl. The concentrated, acidic
methanol fraction, which contains the components with
antimicrobial effect, has been vaporised to an approximate
volume of 50 ml with the help of rotational vacuum
distillation on 35 °C, then it was neutralised to pH 6 with
a 2N NH4OH solution. Then, the neutralised sample has
been completely dried out. That is how the process ended
with a substance with 47.7 mg/ml dry material content,
which was stored in 10 ml distilled water in a sterile tube in a
refrigerator until its application.
Testing of the bioprepatation was conducted on six
clinical samples of Candida species (C. albicans, C. krusei,
C. tropicalis, C. lusitaniae, C.kefyr, and C. glabrata). We
have transferred one unit from each pure culture of the yeast
per species with a sterile inoculation loop to 10 ml
Sabouraud-dextrose culture medium, which has been cul-
tured in a thermostat at 28 °C under aerobic conditions after
vortexing. The yeast cultures picked for testing were set to
0.5 McFarland standard on the following day.
We have transferred 300 μl of each of these cultures and
mixed them with 2.7 ml of soft agar, which has been
previously heated up to 54 °C, then poured them to the
agar plates with a quick movement. After a 20-min wait, the
soft agar settled and holes were made with a 9-mm pin drill,
which were capable of holding substances up to 100 μl [21].
Each plate contained ﬁve holes (Figure 1).
The stock solution was available in 10 ml volumes
(0.47 mg dissolved in 10 ml distilled water), which was
our 100% solution. The distilled water made 80%, 60%,
40%, and 20% dilutions. The dilutions have been performed
according to the macro dilution methods published by
the Clinical and Laboratory Standard Institute [22].
The diluted solutions had the following dry material
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contents: 100% (0.47), 80% (0.38), 60% (0.28), 40% (0.19),
and 20% (0.095) μg/ml. Three parallel series were made.
The sensitivity of tested Candida species to certain
antifungal medications has been determined by paper disk
diffusion method on Mueller–Hinton agar fungi (MHF)
(Figure 2; Table 1). Based on the area of zones of inhibition,
we may differentiate susceptible (S), intermediate (I), and
resistant (R) species. A certain yeast species can be consid-
ered susceptible, if the inhibition zone is ≥20 mm (or
≥10 mm in case of griseofulvin); intermediate, if the
inhibition zone is between 12 and 19 mm; and resistant,
if the inhibition zone is ≤11 mm in vitro [23].
Data analysis was carried out with IBM SPSS Statistics
20.0 software [IBM Corp. Released 2011, Armonk, NY;
descriptive statistics, one-way analysis of variance
(ANOVA)].
RESULTS
The ﬁrst evaluation of the plates was performed after 24 hr
and the zones of inhibition were also measured (Figure 3).
The plates were put in a thermostat for further incubation
and the measurements were carried out again after 48 and
96 hr (Figures 4 and 5).
The vertical axis displays the area of the zones of
inhibition in millimeters, whereas the horizontal axis
displays the tested Candida species. The columns with
different colors represent different dilutions. Certain fungi
species displayed a minor increase in the average area of the
zones of inhibition compared to the 24-hr values. However,
the diameter of the zones remained the same at later tests.
The 96-hr average values of the three parallel zones of
inhibition can be seen in Figure 5. A minor increase in the
diameter can be observed with certain dilutions, but a
decrease could never be observed, not even after 96 hr.
DISCUSSION
We tested the efﬁciency of the antimicrobial proteins
synthesised by X. budapestensis on six different Candida
species isolated from clinical samples with agar diffusion
method. We have worked with ﬁve different dilutions of the
cleaned, protein-rich biopreparation. Based on the results of
the zones of inhibition after a 24-hr incubation period, it can
be observed that the tested protein had an immediate
antifungal effect on the Candida species. Every tested
Candida species showed sensitivity to the 100% dilution,
Figure 1. Agar diffusion technique on Sabouraud agar
Figure 2. Determining the antifungal sensitivity of C. krusei with
paper disk method
Table 1. The sensitivity of Candida species for antifungal medications with paper disk method
Tested active agents C. albicans C. glabrata C. lusitaniae C. kefyr C. tropicalis C. krusei
Origin of yeast from human culture Haemo-culture Cannula Sputum Sputum Wound exudate Trachea
ECO (10 μg) S S S S I I
ITC (50 μg) R R R I R R
FC (1 μg) R I R I R R
FLU (100 μg) R R S I R I
KTC (10 μg) I R R I S S
GRS (10 μg) R R R R R R
AMB (20 ut) R I R S R R
CLT (50 μg) S S S S I S
ECO (50 μg) S S S S S I
MCZ (10 μg) R R R R R R
Note. Abbreviation of antifungal disks according to the manufacturers. AMB: amphotericin B (20 ut); CLT: clotrimazole (50 μg);
FLU: ﬂuconazole(100 μg); ECO 10: econazole (10 μg); ECO 50: econazole (50 μg); ITC: itraconazol (50 μg); FC: ﬂucytosine (1 μg);
KTC: ketoconazole (10 μg); GRS: griseofulvin (10 μg), MCZ: miconazole (10 μg); S: susceptible; I: intermediate; R: resistant.
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as the zones of inhibition have exceeded 20 mm in most of
the cases. C. lusitaniae appeared to be the most sensitive,
whereas C. krusei the least sensitive. The sensitivity has
been conﬁrmed with 80% dilutions as well, the zones of
inhibition were all larger than 20 mm with every fungus. In
case of 60% and 40% dilutions, the Candida species still
showed sensitivity though with less intensity.
Based on our previous research, the 20% dilution was
enough to produce the desired effect [15]. In a similar study
mentioned at the methodology part, the protein produced by
X. cabanillasi called “cabanillasin” had a greater inhibitor
effect on C. krusei and C. lusitaniae than on C. albicans and
C. glabrata after the 24-hr measurement.
However, the activity of cabanillasin on the tested fungi
has decreased after 48 hr in these experiments [17].
Every single tested species showed sensitivity in our
case. After 48 hr, some of the Candida species showed an
increase in the diameter of the zones of inhibition with
certain dilutions, but none of the species showed a
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Figure 4. The average results of the antifungal effects of X. budapestensis at 48 hr
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measured zones of inhibition greater than 20 mm in case of
100%, 80%, 60%, and 40% dilutions.
The last measurement of the zones of inhibition was
carried out after 96 hr. It is observable from the results that
there was no decrease in the diameter of the zones of
inhibition with any of the Candida species. Therefore, it
can be assumed that “fungicide” effect was reached in our
experiment. The dry material content was 0.19 μg/ml, thus
this value can be called the Minimal Fungicidal Concentra-
tion (MFC), which was created by the 40% dilution.
Dry material content was different for each dilution as
they had different protein amounts. Solutions with higher
concentration had more useful proteins with antimicrobial
effect.
There was no relation between the antifungal and XAMP
sensitivity of the Candida species. Despite a considerably
high resistance against other antifungal compounds,
C. lusitaniae showed the highest sensitivity to the proteins
in the biopreparation.
It was important to clarify in this study whether different
concentrations and protein content have any effect on the
intensity and to what degree if there is any. To prove the
hypothesis, we used single-factor ANOVA on 5% signiﬁ-
cance level.
The result of the test is p < .001; therefore, the null
hypothesis, which claims that the generated effect depends
on the dilution, can be conﬁrmed. This proves that our
hypothesis has been conﬁrmed, meaning that signiﬁ-
cantly greater zones of inhibition have been measured at
higher concentration levels and that there is correlation
between the antimicrobial effect and the dilution of the
biopreparation.
CONCLUSIONS
Every tested Candida species has shown sensitivity to
the proteins synthesised by X. budapestensis up to
40% dilution. The area of the zones of inhibition
did not decrease as time passed during our agar diffusion
experiment. We assume that the proteins in the
biopreparation have a “fungicide” effect. The greatest
sensitivity was shown by C. Lusitaniae, whereas
C. krusei was the least sensitive. Our results con-
ﬁrmed the previous experiments in which C. albicans
showed sensitivity to the antimicrobial protein of
X. cabanillasi [17].
The frequent and unprofessional usage of antifungal
medications signiﬁcantly decreases the sensitivity of
fungi towards these products. Reasons behind the
resistance mechanism may include: decreased amount of
active agents get into the cell, increased amount of active
agents are excreted through the efﬂux pumps, or the target
molecule is modiﬁed [24]. There is an increasing need to
develop new antifungal medications with new mechanisms
and with different active agents.
During our previous studies, we have also con-
ﬁrmed the bactericide effect of the biopreparation of
X. budapestensis on Gram-positive and Gram-negative
bacteria. Gram-positive bacteria were more sensitive, but
every tested bacterium showed sensitivity to even the 20%
dilution [15].
ABBREVIATIONS
bicA : bicornutin-A gene
CFCM : cell-free culture media
HCL : hydrogen chloride
MALDI : matrix-assisted laser desorption/ionisation
MeOH : methyl alcohol
MFC : minimal fungicidal concentration
MHF : Mueller–Hinton agar fungi
NH4OH : ammonium hydroxid
PF : puriﬁed fraction
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Figure 5. The average results of the antifungal effects of X. budapestensis at 96 hr
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SD : Sabouraud dextrose agar
XAMP : Xenorhabdus antimicrobial peptide
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